COMBINED THERAPY FOR TREATING CANCER USING A RECOMBINANT POXVIRUS EXPRESSING A TUMOR ANTIGEN AND AN ANTAGONIST OR AGONIST OF AN IMMUNE CONTROL POINT MOLECULE Russian patent published in 2020 - IPC A61K39/00 A61P35/00 

FIELD: medicine; oncology.

SUBSTANCE: group of inventions can be used in treating cancer. Methods of the invention involve administering to a patient a recombinant poxvirus coding a polypeptide containing at least one tumor-associated antigen (TAA) selected from a group, consisting of carcinoembryonal antigen (CEA), mucin 1 bound to cell surface (MUC-1), prostate-specific antigen (PSA) and human epidermal growth factor receptor 2 (HER-2), as well as an antagonist PD-1, which is an antibody, and an antagonist CTLA-4, which is an antibody. Pharmaceutical combinations according to the invention comprise a recombinant poxvirus encoding a polypeptide, containing at least one TAA, as well as antagonist PD-1 and antagonist CTLA-4, which are antibodies.

EFFECT: using the inventions allows increasing the survival rate, reducing the tumor load, intensifying the T-cell response ensured by the synergetic effect of the combination.

28 cl, 1 tbl, 23 dwg, 43 ex